Top Story Today
Novo Built the Whole Trial Around Beating Lilly. Then Lost.
CagriSema hit 23% weight loss over 84 weeks. Impressive in a vacuum, except Lilly's Zepbound posted 25.5% in the exact same study. Novo designed this trial specifically to prove its drug was at least as good. It wasn't, and shares cratered 15% to $40.20 premarket. The really awkward part? Novo already submitted CagriSema for FDA review before these results dropped, so regulators will still weigh in by late 2026. A higher-dose trial is planned for the second half of this year, but being slightly worse than the market leader — even with a novel amylin mechanism — doesn't exactly scream premium pricing.
Why it matters: This result reshapes the entire obesity arms race. Winning won't come down to shaving off an extra percentage point of weight loss — it'll come down to supply chains, manufacturing scale, and which company doctors trust. For every biotech piling into obesity, Novo's stumble is a cautionary tale: head-to-head trials can make your career or end your strategy overnight.
Read more →Deals & M&A
Gilead Pays a 68% Premium for the CAR-T Therapy Oncologists Already Prefer
Gilead is shelling out $7.8B to acquire Arcellx and its BCMA CAR-T therapy anito-cel, which faces an FDA decision in December 2026. Doctors already favor it over J&J and Legend's Carvykti on safety. A $5/share contingent payment kicks in at $6B in cumulative sales by 2029. With Gilead's existing cell therapy revenue down 7% in 2025, this isn't aspirational — it's a rescue mission.
Read more →Lilly Bets $1.84B That You Can Retrain the Immune System Instead of Suppressing It
Lilly's $85M upfront deal with Repertoire Immune Medicines bets on restoring immune tolerance — essentially teaching the body to stop attacking itself rather than sledgehammering the immune system into submission. If it works, autoimmune patients could see durable remission instead of lifelong drug regimens. Repertoire already partners with Roche and BMS, and the milestone-heavy deal structure signals conviction with guardrails.
Read more →Moderna Sells a Late-Stage Rare Disease Asset for What Analysts Call 'Garage Sale' Prices
Just $50M upfront plus $110M in milestones for mRNA-3927, a late-stage therapy for propionic acidemia. Leerink analysts called it a garage sale, and it's hard to argue. Nobody was exactly fighting over Moderna's rare disease portfolio. With CMO Jacqueline Miller departing in March, this looks like a quiet retreat from rare disease toward oncology.
Read more →$205M for a Regulatory Voucher — Not a Single Drug Sold
Fortress subsidiary Cyprium Therapeutics will pocket $164M after paying NICHD its 20% cut from selling a Priority Review Voucher earned through an FDA approval for Menkes disease. The actual drug's commercial rights already went to Sentynl. That $205M price tag confirms buyer demand for these vouchers is alive and well, validating a business model where regulatory assets fund rare disease companies entirely independent of product sales.
Read more →Clinical & Regulatory
One Gene Therapy Shot Could Replace a Lifetime of Dietary Restrictions
Ultragenyx's DTX401 just scored Priority Review with an August 23 PDUFA date, putting it on track to become the first therapy targeting the root genetic defect in glycogen storage disease type Ia. Instead of lifelong dietary management, patients could get a single treatment. Manufacturing at Ultragenyx's own Bedford, Massachusetts facility sidesteps the outsourcing bottlenecks that have plagued other gene therapy launches.
Read more →After a 90% Stock Crash, MoonLake Just Nailed Its Fifth Positive Indication
MoonLake badly needed a win after a brutal 2025 miss in hidradenitis suppurativa tanked its stock 90%. Sonelokimab, an IL-17A/F nanobody, hit 81% ASAS40 response in axial spondyloarthritis. PET imaging showed it reduced both inflammation and bone-forming osteoblast activity in sacroiliac joints within 12 weeks — the kind of irreversible damage that drives long-term disability. An NDA filing for psoriatic arthritis is planned for late 2026.
Read more →This Drug Missed Its Primary Endpoint. They're Filing for Approval Anyway.
Gossamer Bio's seralutinib produced a 13-meter improvement in six-minute walk distance for pulmonary arterial hypertension patients — directionally positive but statistically insignificant. Cough hit 37% of treated patients. Filing anyway is a bold bet on FDA flexibility in orphan diseases, highlighting the growing tension between statistical significance and regulatory pragmatism for serious conditions with few options.
Read more →Vanda's Stock Jumped 40% on an Approval That Skipped Phase 3 Entirely
The FDA approved milsaperidone (branded Bysanti) for bipolar I and schizophrenia using bioequivalence data and over 100,000 patient-years of safety history from its parent compound iloperidone — no new Phase 3 trials needed. Launch is planned for Q3 2026. After Vanda spent seven years failing to expand Hetlioz into jet lag, this win proves formulation innovation faces a far lower regulatory bar than novel mechanism expansion in CNS.
Read more →A Three-Month FDA Delay Just Handed BioMarin Free Runway Against Its Biggest Rival
Ascendis Pharma's achondroplasia therapy TransCon CNP got bumped to a February 28, 2026 PDUFA date after the FDA classified revised post-marketing protocols as a major amendment. That gives BioMarin's Voxzogo three extra months to lock down prescribing habits and reimbursement. TransCon CNP offers once-weekly dosing versus Voxzogo's daily injections, but first mover advantage compounds fast in pharma.
Read more →Industry Trends & Strategy
Pfizer's Monthly Weight-Loss Shot Just Quietly Posted Numbers Nobody Expected
PF-3944 delivered 12.3% placebo-adjusted weight loss at week 28 after patients transitioned from weekly loading doses to monthly maintenance injections — and the curve hadn't plateaued yet. Pfizer is planning over 10 Phase 3 trials launching throughout 2026. In an obesity market dominated by weekly regimens from Lilly and Novo, monthly dosing could be a genuine differentiator for patients who dread injecting every seven days.
Read more →Big Pharma Has Stopped Pretending to Care About Early-Stage Rare Disease
Major pharma companies are systematically passing on early-stage rare disease programs, chasing post-Phase 2 assets with clear regulatory pathways and scalable manufacturing instead. The result is a two-tier funding market where late-stage programs command premium valuations while early-stage rare disease biotechs starve for capital. AI-powered drug repurposing is emerging as a cheaper alternative to traditional early discovery bets.
Read more →NIH Funding Cuts Are Forcing Clinical Trials to Redesign From Scratch
Over $83M in federal research funding was canceled and 383 NIH-funded trials lost support in 2025, forcing a fundamental rethink of trial design. Execution quality — milestone discipline, funding resilience, enrollment speed — now matters as much as the science itself when investors value an asset. The FDA is deploying agentic AI for protocol review as the entire trial architecture evolves.
Read more →Sanofi's CEO Gets the Boot as Its Largest Shareholder Installs a Replacement
Sanofi's largest shareholder orchestrated the removal of CEO Paul Hudson and installed Merck KGaA's Belén Garijo as his replacement. The move immediately raises questions about Sanofi's commitment to rare disease, its obesity pipeline, and its innovation strategy. Garijo's tenure at Merck KGaA emphasized technology partnerships and diversified therapeutic focus, potentially signaling a pivot toward higher-volume indications.
Read more →